Skip to main content

Table 1 Baseline characteristics of study population

From: Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials

Study

n

Age (Years)

Viral Status (C/B/C+B)

Alcohol Intake@ (No/Yes)

Tumor Size (mm)

Tumor no

Child Pugh (A/B)

Treatment (Surgery/Local)

Follow up

Mizuta et al.

Treatment

32

63.3 ± 7.5

28/3/1

10/22

17.7 ± 5.1

1.5 ± 0.9

26/6

1/31

28.9 (± 8.3)

Control

29

64.5 ± 6.7

26/2/1

3/26

19.4 ± 6.9

1.5 ± 0.7

22/7

3/26

27.7 (± 8.6)

Kakizaki et al.

Treatment

30

69.1 ± 5.9

30/0/0

6/24

20.4 ± 11.6

19/11

22/8

4/26/0

36

Control

30

69.0 ± 7

30/0/0

3/27

25.0 ± 9.4

22/8

22/8

7/23/0

36

Hotta et al.

Treatment

21

 

14/6

 

18/3*

15/6

15/6

2/19

 

Control

21

 

3/19

 

18/6*

12/12

12/12

2/22

 

Yoshiji et al.

Treatment

18*

62.8 ± 7.4

15/0

8/10

17.9 ± 9.2

1.6 ± 0.9

16/2

0/18

36

Control

25

60.5 ± 8.5

1/3

12/13

18.7 ± 9.5

1.6 ± 0.9

20/5

0/25

36

Yoshida et al.

Treatment#

367

68.6 ±

305/38

140/227

19.9 ± 7.6

1.4 ± 0.7

323/44

14/353

37

Control

181

7.9

150/20

79/102

20.3 ± 7.6

1.4 ± 0.7

154/27

7/174

37

  1. *The data in the treatment group of Yoshiji et al. is restricted to 18 patients to exclude 19 patients who received ACE-inhibitors and 25 patients who received a combination of ACE-Inhibitors and Vitamin K2.
  2. @Mizuta et al. and Yoshiji et al. have defined heavy alcoholism by consumption greater than 40 grams/day whereas Kakizaki et al. has defined it as greater than 65 gm/dl. Yoshida et al. has defined at as consumption greater than thrice days per week regardless of the quantity.
  3. #The treatment group in the study of Yoshida et al. compromised 367 patients, of whom 182 received drug at a dosage of 45 mg/day whereas the remaining 185 at 90 mg/day. The dosages in all the other studies is 45 mg/day.